Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency Syndrome - 10/09/11
National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Groupfn3
Joe Wheat, MD a, b, ⁎, Samantha MaWhinney, DSc c, Richard Hafner, MD d, David McKinsey, MD e, Dafeng Chen, PhD c, Ann Korzun, MS c, Kenneth J. Shakan, MD f, Phillip Johnson, MD g, Richard Hamill, MD h, David Bamberger, MD i, Peter Pappas, MD j, John Stansell, MD k, Susan Koletar, MD l, Kathleen Squires, MD m, Robert A. Larsen, MD n, Tony Cheung, MD o, Newton Hyslop, MD p, Kwan Kew Lai, MD q, Debra Schneider, MS r, Carol Kauffman, MD s, Michael Saag, MD j, William Dismukes, MD j, William Powderly, MD tAbstract |
PURPOSE: This study assesses the efficacy and safety of fluconazole therapy in patients with acquired immunodeficiency syndrome (AIDS) and mild to moderately severe manifestations of disseminated histoplasmosis.
PATIENTS AND METHODS: This was a multicenter, open-label, nonrandomized prospective trial. All patients had AIDS and disseminated histoplasmosis. Patients were treated with 1,200 mg of fluconazole given by mouth once on the first day, then 600 mg once daily for 8 weeks, and those patients who improved clinically were then assigned fluconazole maintenance therapy 200 mg once daily for at least 1 year. Interim analysis revealed a high failure rate (10 of 20, 50%), causing revision of the protocol to increase the fluconazole dose to 1,600 mg given once on the first day, then 800 mg once daily, and the duration to 12 weeks for induction therapy and then 400 mg daily for 1 year for maintenance therapy.
MEASUREMENTS AND MAIN RESULTS: Thirty-six of 49 patients (74%; 95% confidence interval [CI]: 59% to 85%) with mild to moderately severe clinical manifestations who entered into the revised study responded to 800 mg of fluconazole daily for 12 weeks as induction therapy. Of the seven patients who failed induction therapy because of progression of histoplasmosis, one died of the infection. Of 36 patients who entered into the maintenance phase of the study receiving 400 mg of fluconazole daily for 1 year, 11 (30.5%) relapsed, including one who died (2.8%). Two of the 49 patients (4.1%) were removed because of grade 4 adverse events, alkaline phosphatase elevation for one and aspartate aminotransferase elevation in the other. The relapse-free rate at 1 year was 53% (95% CI: 32% to 89%), prompting closure of the study.
CONCLUSIONS: Fluconazole 800 mg daily is a safe and moderately effective induction therapy for mild or moderately severe disseminated histoplasmosis in patients with AIDS. On the basis of historic comparison, fluconazole 400 mg daily is less effective than itraconazole 200 to 400 mg daily or amphotericin B 50 mg given weekly as maintenance therapy to prevent relapse.
Le texte complet de cet article est disponible en PDF.Plan
Vol 103 - N° 3
P. 223-232 - septembre 1997 Retour au numéro
Article précédent
- Efficacy of a High and Accelerated Dose of Hepatitis B Vaccine in Alcoholic Patients : A Randomized Clinical Trial
- Alan S. Rosman, Prithwijit Basu, Kathryn Galvin, Charles S. Lieber
- Skeletal Status of Men with Early and Late Ankylosing Spondylitis
- Y.S.Lynda Lee, Tammi Schlotzhauer, Susan M. Ott, Ronald F. van Vollenhoven, John Hunter, Jay Shapiro, Robert Marcus, James L. McGuire
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?